12:00 AM
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Undisclosed synthetic steroid: IND accepted

pSivida said FDA cleared an IND for an undisclosed posterior uveitis candidate to move straight into Phase III testing. The IND allows the company to conduct a pair of Phase III trials with a primary endpoint of recurrence of uveitis within 12 months....

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >